The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a high-priority public alert following the discovery of several counterfeit versions of critical cancer drugs circulating within the country. The agency is warning healthcare providers, oncologists, and patients to exercise extreme vigilance, as these falsified products pose life-threatening risks to those already battling advanced malignancies.
Major Oncology Brands Compromised
The latest warnings, formalized through a series of public alerts in March 2026, specifically identify counterfeit batches of Avastin (Bevacizumab), Herceptin (Trastuzumab), Mabthera (Rituximab), and Tecentriq (Atezolizumab). These medications are cornerstones in the treatment of various cancers, including breast cancer, colorectal cancer, and glioblastoma.
According to NAFDAC, the alarm was first raised by the Marketing Authorization Holder (MAH), Roche Nigeria, after reports from local hospitals indicated suspicious packaging and unexpected physical characteristics in vials brought in by patients. For instance, in one confirmed case of counterfeit Phesgo (600mg), the vial volume was found to be 20ml instead of the standard 10ml.
Key Red Flags for Healthcare Providers
Investigations into the seized samples have revealed sophisticated yet detectable flaws. NAFDAC has highlighted several discrepancies that medical professionals and caregivers should look for:
Batch Inconsistencies: Many of the fake products carry batch numbers that do not exist in the official manufacturer databases.
Packaging Errors: Visible spelling mistakes on the artwork and incorrect font placements are common markers of these illicit products.
Security Labeling: The Tamper Evidence labels on the counterfeit vials do not correspond to the genuine materials used by authorized manufacturers.
Mobile Authentication Service (MAS): In several instances, the MAS labels (such as Sproxil or Mpdigree) used on the packaging did not match the authorized distributors for the Nigerian market.
The Risk to Public Health
NAFDAC Director-General has emphasized that counterfeit medicines are a "silent killer." Because these products bypass regulatory oversight, they may contain no active ingredients, incorrect dosages, or toxic substances. For a cancer patient, the use of a falsified drug leads to treatment failure, allowing the disease to progress unchecked while potentially causing severe adverse reactions or poisoning.
"The illegal marketing of counterfeit medicines does not guarantee safety, quality, or efficacy. It is a direct attack on the most vulnerable members of our society," the agency stated in its official notice.
Nationwide "Mop-Up" Operations
In response to these findings, NAFDAC has directed its zonal directors and state coordinators to conduct immediate surveillance and "mop up" the counterfeit products from the supply chain. The agency is particularly targeting open drug markets, such as those in Lagos, Kaduna, and Gombe, where these illicit batches were reportedly traced.
Guidance for Patients and Facilities
NAFDAC strongly advises that all medical products be obtained strictly from authorized and licensed suppliers. Patients are encouraged to verify their medications through the following channels:
Inspect the physical condition: Check for unusual seals, discoloration, or labeling errors.
Report suspicious products: Contact the nearest NAFDAC office or call the toll-free hotline at 0800-162-3322.
Digital Reporting: Use the "Med-safety" application or email sf.alert@nafdac.gov.ng to report adverse events or suspected fakes.
The agency remains committed to purging the Nigerian pharmaceutical market of substandard and falsified medicines to ensure that life-saving treatments remain exactly that life-saving.